MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/rheumatology/keae099

Медицинская библиотека · Rheumatology (Oxford, England) · 2025

Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement.

Vermeulen Olof C B, Brouwer Elisabeth, Slart Riemer H J A, Sandovici Maria, Rutgers Abraham, Hilterman T Jeroen, Hiddinga Birgitta, Oosting Sjoukje F, Jalving Mathilde, de Heij Albert H, Knapen Daan G, Hospers Geke A P, van der Geest Kornelis S M

СтатьяСравнительное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVES

To compare clinical characteristics, imaging findings and treatment requirements of patients with immune checkpoint inhibitor-mediated polymyalgia rheumatica (ICI-PMR) and primary PMR.

METHODS

This single centre, retrospective cohort study compared ICI-PMR in patients with cancer (n = 15) to patients with primary PMR (n = 37). A comparison was made between clinical symptoms, laboratory markers, ultrasonography, 18F-FDG-PET/CT findings and treatment requirements related to PMR.

RESULTS

Patients with ICI-PMR less frequently fulfilled the EULAR/ACR classification criteria for PMR (66.7%) than patients with primary PMR (97.3%). Morning stiffness, weight loss and elevation of the ESR were less frequently seen in patients with ICI-PMR. No differences were observed regarding the presence of inflammatory lesions on ultrasound of the shoulders and hips between the two groups. The Leuven and the Leuven/Groningen 18F-FDG-PET/CT scores were significantly lower in the ICI-PMR group. Finally, the ICI-PMR group could be managed with lower glucocorticoid doses than the primary PMR group, while this treatment could be discontinued more quickly.

CONCLUSION

Our findings indicate that ICI-PMR may have a milder course with less intense inflammation than primary PMR. ICI-PMR can be managed with a relatively low glucocorticoid dose. Our study underscores that ICI-PMR should be regarded as a PMR-like syndrome.

Для цитирования: Vermeulen Olof C B, Brouwer Elisabeth, Slart Riemer H J A, Sandovici Maria, Rutgers Abraham, Hilterman T Jeroen, Hiddinga Birgitta, Oosting Sjoukje F, Jalving Mathilde, de Heij Albert H, Knapen Daan G, Hospers Geke A P, van der Geest Kornelis S M. Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement.. Rheumatology (Oxford, England). 2025. DOI: 10.1093/rheumatology/keae099.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.